Global gene therapy market is projected to witness a CAGR of 22.13% during the forecast period 2024-2031F
Home>Industry Reports>Gene Therapy Market Assessment, Opportunities and Forecast, 2017-2031F
Global gene therapy market is projected to witness a CAGR of 22.13% during the forecast period 2024-2031F, growing from USD 7,640 million in 2023 to USD 37,830 million in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
The global gene therapy market is expected to experience robust growth, due to various factors such as increasing prevalence of chronic diseases and genetic disorders, technological advancements, and innovations in gene editing technologies, and growing popularity of personalized medicine along with favorable regulatory frameworks. Additionally, rise in new product launches and increased collaboration activities among the biotechnological companies and other related firms is leading to immense growth of global gene therapy market.
The global gene therapy market is experiencing rapid expansion, majorly due to increased prevalence of chronic diseases and genetic disorders worldwide. As the global elderly population is increasing, the prevalence of chronic diseases is rising, leading to the increased demand for gene therapies to combat these fatal diseases. Technological advancements such as innovation in gene editing technologies, including techniques such as CRISPR-Cas9 and TALEN, that have revolutionized the precision and efficiency of gene therapy has further contributed to the growth of the market at a global level. Increased government initiatives to enhance research and development activities in gene therapy, along with increased interest of leading market players to invest in the industry is fueling the growth of global gene therapy market.
The rising interest in personalized medicine is another major driving factor of gene therapy market, as gene therapy offers tailored treatment strategies based on an individual's genetic profile and follows a patient-centric care approach. Increased collaborative efforts and partnership agreements have accelerated growth in this market as these ventures assist in bringing innovation and advancements in gene therapy technology. Moreover, favorable, and supportive regulatory framework, that allows increased patent approvals, safe and efficient review processes and flexible pathways is leading to tremendous growth of the global gene therapy market.
The demand for gene therapy is increasing significantly due to the rising prevalence of chronic diseases. Increasing aging population is responsible for onset of several chronic health conditions such as cardiovascular diseases, cancer, and autoimmune diseases. These chronic diseases are fatal and need continuous research and development activities to bring innovative therapeutics such as gene therapies. According to WHO 2023 statistics, chronic diseases are the most common diseases affecting people from all over the world and is responsible for 41 million deaths every year worldwide. Sedentary lifestyle, unhealthy diet, obesity, excessive tobacco, and alcohol consumption are the leading risk factors for the rising prevalence of chronic diseases among the population. The insufficient availability of successful therapies for treating chronic illnesses has increased emphasis on bringing innovation and advancements in gene therapy techniques, which has consequently increased the necessity for conducting advanced research and development activities in gene therapy market. Due to these factors, the global gene therapy market size is increasing.
Technological advancements such as artificial intelligence plays a crucial role in global gene therapy market. AI is being used in various phases of research during the development of gene therapies, to analyze extensive genomic details, identify precise gene target areas, predicting the potential treatment outcomes, and analyzing different genetic material delivery methods. Application of AI in exploring genetic data expedites the discovery and advancement of gene therapies. Due to it, the extensive use of AI in development of gene therapies is further escalating growth of global gene therapy market. Several innovative firms are increasing their use of AI in exploring gene therapy techniques. For instance, in March 2023, DeepMind scientists developed a tiny 'syringe' for injecting gene therapy and tumor-killing drugs using Google's AI based technology. The syringe developed using Google’s AlphaFold AI system, is capable of directly delivering proteins, including cancer-fighting medications and gene therapies into human cells. These innovative technological advancements are propelling the global gene therapy market growth.
Among the vector segment, viral vectors hold a significant market share in the overall global gene therapy market. The increasing demand for adeno-associated virus (AAV) vectors in gene therapy is significantly propelling the global gene therapy market. AAV vectors have proved to be highly efficient vectors for delivering genetic materials to the targeted tissues. These vectors are safe and have high specificity, due to which these are majorly used in the treatment of various diseases such as rare genetic disorders and cancer.
Several researchers and biotech companies are investing in developing gene therapies using AAV vectors. For instance, in July 2023, Astellas announced to enter into a substantial agreement with 4D Molecular Therapeutics, which is a well-known firm that focuses on treating rare eye diseases. The partnership agreement will allow Astellas to gain rights to use the intravitreal retinotropic R100 vector, which is an AAV vector that was invented by 4D Molecular Therapeutics for intravitreal genetic material delivery. The growing interest of innovative players in investing in using viral vectors is accelerating the growth of global gene therapy market.
Among the application segment, oncological disorders hold a significant market share in global gene therapy market. Increased worldwide prevalence of cancer leads to increased investments by the major players to develop efficient gene therapies to treat cancer. With the emergence of cell-based immunotherapy, such as chimeric antigen receptor (CAR) T-cell therapy, gene therapy has become a potent tool in the immuno-oncology arsenal, redirecting immune cells against cancer cells with remarkable success. The ability of gene therapy to offer targeted and personalized treatments for oncological diseases is reshaping the landscape of cancer treatment. The increasing application of gene therapy in oncological diseases is significantly driving the demand for gene therapy treatments. Due to it, there has been increased FDA approvals, for instance, in December 2022, Ferring Pharmaceuticals announced that it has received FDA approval for “Adstiladrin”, which is a novel adenovirus vector-based gene therapy, designed to provide treatment of invasive bladder cancer in the adult patients. These growing research and development activities in gene therapies for the treatment of cancer, along with favorable regulatory frameworks is escalating the growth of global gene therapy market.
North America holds the maximum share in global gene therapy market. The United States is well-known for its robust healthcare infrastructure and world class healthcare facilities, which leads to increased investments by the major players in conducting quality research and development activities in gene therapies. Due to it, the region is dominating the global gene therapy market. For instance, Iovance Biotherapeutics, Inc. announced that it has received FDA approval for “AMTAGVI”. It is a tumor-derived autologous T-cell immunotherapy, specially designed for the treatment of metastatic melanoma in adult patients. Moreover, the presence of key market players, such as Bristol-Myers Squibb Company and Amgen, Inc. in the region, further accelerate the growth of gene therapy market in North America.
The future of global gene therapy market appears promising due to several driving key factors. Increased prevalence of chronic diseases worldwide, rapidly ongoing advancements in gene editing technologies, such as CRISPR-Cas9 and other emerging techniques, are enhancing the efficiency of gene therapy. These innovative technological advancements enable scientists to target and modify specific genes with high accuracy and assist in discovering treatment for a wide range of diseases. Favorable and supportive regulatory frameworks worldwide are increasingly recognizing the potential of gene therapy and adopting more flexible and expedited review processes for these innovative treatments. Due to it, there has been increased investment activities by major players in pharmaceutical and biotech industry, leading to the development of a robust pipeline of gene therapy candidates across a wide spectrum of medical conditions. Increased research and development in developing personalized medicine, along with increased collaboration activities are driving the growth of global gene therapy market in the forecasted period.
Report Scope
“Gene Therapy Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gene therapy market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
Report Attribute |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2017-2022 |
Forecast Period |
2024-2031F |
Projected Growth Rate |
CAGR of 22.13% between 2024 and 2031F |
Revenue Forecast in 2031 |
USD 37,830 million |
Segments Covered |
Type, Vector, Gene Delivery Method, Application, Route of Administration, End-user |
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
Key Companies Profile |
Gilead Sciences Inc. (Kite Pharma), Novartis AG, CSL Behring LLC (Manufactured by uniQure N.V.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc. (Janssen Research & Development, LLC), Amgen, Inc., Sarepta Therapeutics, Inc., F. Hoffmann-la Roche ltd. (Spark Therapeutics, Inc.), JW Therapeutics (Shanghai) Co. Ltd., Bluebird Bio Inc. |
Customization Scope |
15% free report customization with purchase |
Pricing and Purchase Options |
Avail the customized purchase options to fulfill your precise research needs |
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
Download Free Sample Report
In the report, global gene therapy market has been segmented into the following categories:
· By Type
o Gene Augmentation
o Gene Silencing
o Others
o Viral Vectors
o Non-Viral Vectors
o In vivo
o Ex vivo
o Oncological Diseases
o Genetic Diseases
o Cardiovascular Diseases
o Neuromuscular Diseases
o Hematological Diseases
o Infectious Diseases
o Others
o Intravenous
o Others
o Hospitals
o Cancer and Research Institutes
o Clinics
o Others
· By Region
o North America
o Europe
o Asia-Pacific
o South America
o Middle East and Africa
Key Players Landscape and Outlook
In global gene therapy market, major pharmaceutical and biotechnology companies are entering into partnerships and collaborations. These collaborations facilitate effective utilization of resources, knowledge, and expertise, leading to expediting the development and commercialization of gene therapies. For pharmaceutical leaders, collaboration with innovative biotechnology firms allows them to enhance and diversify their product portfolios and assist in developing innovative gene therapy solutions.
For instance, in May 2023, Novartis, which is an innovative healthcare solutions company, announced to acquire Avrobio’s rare disease gene therapy. Through the acquisition, Novartis aims to enhance and expand its product portfolio of innovative cell and gene therapy segment. The investment signifies Novartis’s commitment to expand its presence in these critical therapeutic areas, leveraging its capabilities to bring innovation and development of novel treatments. These collaborative ventures further assist in elevating the global gene therapy market.
Key Players Operating in the Global Gene Therapy Market are:
· Gilead Sciences Inc. (Kite Pharma)
· Novartis AG
· CSL Behring LLC (Manufactured by uniQure Inc.)
· Bristol-Myers Squibb Company
· Johnson & Johnson Services, Inc. (Janssen Research & Development, LLC)
· Amgen, Inc.
· Sarepta Therapeutics, Inc.
· F. Hoffmann-la Roche ltd. (Spark Therapeutics, Inc.)
· JW Therapeutics (Shanghai) Co. Ltd.
· Bluebird Bio, Inc.
Markets and Data report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global gene therapy market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Gene Therapy Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1.By Value
4.1.2.By Volume
4.2. By Type
4.2.1.Gene Augmentation
4.2.2.Gene Silencing
4.2.3.Others
4.3. By Vector
4.3.1.Viral Vectors
4.3.2.Non-Viral Vectors
4.4. By Gene Delivery Method
4.4.1.In vivo
4.4.2.Ex vivo
4.5. By Application
4.5.1.Oncological Diseases
4.5.2.Genetic Diseases
4.5.3.Cardiovascular Diseases
4.5.4.Neuromuscular Diseases
4.5.5.Hematological Diseases
4.5.6.Infectious Diseases
4.5.7.Others
4.6. By Route of Administration
4.6.1.Intravenous
4.6.2.Others
4.7.1.Hospitals
4.7.2.Cancer and Research Institutes
4.7.3.Clinics
4.7.4.Others
4.8. By Region
4.8.1. North America
4.8.2. Europe
4.8.3. Asia-Pacific
4.8.4. South America
4.8.5. Middle East and Africa
4.9. By Company Market Share (%), 2023
5. Global Gene Therapy Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2.By Type
5.1.2.1. Gene Augmentation
5.1.2.2. Gene Silencing
5.1.2.3. Others
5.1.3.By Vector
5.1.3.1. Viral Vectors
5.1.3.2. Non-Viral Vectors
5.1.4.By Gene Delivery Method
5.1.4.1. In vivo
5.1.4.2. Ex vivo
5.1.5.By Application
5.1.5.1. Oncological Diseases
5.1.5.2. Genetic Diseases
5.1.5.3. Cardiovascular Diseases
5.1.5.4. Neuromuscular Diseases
5.1.5.5. Hematological Diseases
5.1.5.6. Infectious Diseases
5.1.5.7. Others
5.1.6.By Route of Administration
5.1.6.1. Intravenous
5.1.6.2. Others
5.1.7.By End-user
5.1.7.1. Hospitals
5.1.7.2. Cancer and Research Institutes
5.1.7.3. Clinics
5.1.7.4. Others
5.1.8.United States*
5.1.8.1. Market Size & Forecast
5.1.8.1.1. By Value
5.1.8.1.2. By Volume
5.1.8.2. By Type
5.1.8.2.1. Gene Augmentation
5.1.8.2.2. Gene Silencing
5.1.8.2.3. Others
5.1.8.3. By Vector
5.1.8.3.1. Viral Vectors
5.1.8.3.2. Non-Viral Vectors
5.1.8.4. By Gene Delivery Method
5.1.8.4.1. In vivo
5.1.8.4.2. Ex vivo
5.1.8.5. By Application
5.1.8.5.1. Oncological Diseases
5.1.8.5.2. Genetic Diseases
5.1.8.5.3. Cardiovascular Diseases
5.1.8.5.4. Neuromuscular Diseases
5.1.8.5.5. Hematological Diseases
5.1.8.5.6. Infectious Diseases
5.1.8.5.7. Others
5.1.8.6. By Route of Administration
5.1.8.6.1. Intravenous
5.1.8.6.2. Others
5.1.8.7. By End-user
5.1.8.7.1. Hospitals
5.1.8.7.2. Cancer and Research Institutes
5.1.8.7.3. Clinics
5.1.8.7.4. Others
5.1.9.Canada
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.Spain
5.2.5.Netherlands
5.2.6.Poland
5.2.7.Russia
5.2.8.United Kingdom
5.3. Asia-Pacific
5.3.1.China
5.3.2.Japan
5.3.3.Australia
5.3.4.South Korea
5.3.5.India
5.4. South America
5.4.1.Brazil
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
6. Market Mapping, 2023
6.1. By Type
6.2. By Vector
6.3. By Gene Delivery Method
6.4. By Application
6.5. By Route of Administration
6.6. By End-user
6.7. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1.Political Factors
7.4.2.Economic System
7.4.3.Social Implications
7.4.4.Technological Advancements
7.4.5.Environmental Impacts
7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.5.1.Supplier Power
7.5.2.Buyer Power
7.5.3.Substitution Threat
7.5.4.Threat from New Entrant
7.5.5.Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Gilead Sciences Inc. (Kite Pharma)
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Novartis AG
13.3. CSL Behring LLC (Manufactured by uniQure Inc.)
13.4. Bristol-Myers Squibb Company
13.5. Johnson & Johnson Services, Inc. (Janssen Research & Development, LLC)
13.6. Amgen, Inc.
13.7. Sarepta Therapeutics, Inc.
13.8. F. Hoffmann-la Roche ltd. (Spark Therapeutics, Inc.)
13.9. JW Therapeutics (Shanghai) Co. Ltd.
13.10. Bluebird Bio, Inc
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer
List Of Figure:
Figure 1 Global Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 2 Global Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 3 Global Gene Therapy Market Share (%), By Type, 2017-2031F
Figure 4 Global Gene Therapy Market Share (%), By Vector, 2017-2031F
Figure 5 Global Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
Figure 6 Global Gene Therapy Market Share (%), By Application, 2017-2031F
Figure 7 Global Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
Figure 8 Global Gene Therapy Market Share (%), By End-user, 2017-2031F
Figure 9 Global Gene Therapy Market Share (%), By Region, 2017-2031F
Figure 10 North America Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 11 North America Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 12 North America Gene Therapy Market Share (%), By Type, 2017-2031F
Figure 13 North America Gene Therapy Market Share (%), By Vector, 2017-2031F
Figure 14 North America Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
Figure 15 North America Gene Therapy Market Share (%), By Application, 2017-2031F
Figure 16 North America Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
Figure 17 North America Gene Therapy Market Share (%), By End-user, 2017-2031F
Figure 18 North America Gene Therapy Market Share (%), By Country, 2017-2031F
Figure 19 United States Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 20 United States Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 21 Canada Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 22 Canada Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 23 Europe Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 24 Europe Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 25 Europe Gene Therapy Market Share (%), By Type, 2017-2031F
Figure 26 Europe Gene Therapy Market Share (%), By Vector, 2017-2031F
Figure 27 Europe Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
Figure 28 Europe Gene Therapy Market Share (%), By Application, 2017-2031F
Figure 29 Europe Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
Figure 30 Europe Gene Therapy Market Share (%), By End-user, 2017-2031F
Figure 31 Europe Gene Therapy Market Share (%), By Country, 2017-2031F
Figure 32 Germany Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 33 Germany Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 34 France Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 35 France Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 36 Italy Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 37 Italy Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 38 Spain Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 39 Spain Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 40 Netherlands Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 41 Netherlands Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 42 Poland Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 43 Poland Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 44 Russia Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 45 Russia Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 46 United Kingdom Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 47 United Kingdom Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 48 Asia-Pacific Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 49 Asia-Pacific Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 50 Asia-Pacific Gene Therapy Market Share (%), By Type, 2017-2031F
Figure 51 Asia-Pacific Gene Therapy Market Share (%), By Vector, 2017-2031F
Figure 52 Asia-Pacific Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
Figure 53 Asia-Pacific Gene Therapy Market Share (%), By Application, 2017-2031F
Figure 54 Asia-Pacific Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
Figure 55 Asia-Pacific Gene Therapy Market Share (%), By End-user, 2017-2031F
Figure 56 Asia-Pacific Gene Therapy Market Share (%), By Country, 2017-2031F
Figure 57 China Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 58 China Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 59 Japan Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 60 Japan Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 61 Australia Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 62 Australia Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 63 South Korea Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 64 South Korea Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 65 India Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 66 India Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 67 South America Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 68 South America Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 69 South America Gene Therapy Market Share (%), By Type, 2017-2031F
Figure 70 South America Gene Therapy Market Share (%), By Vector, 2017-2031F
Figure 71 South America Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
Figure 72 South America Gene Therapy Market Share (%), By Application, 2017-2031F
Figure 73 South America Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
Figure 74 South America Gene Therapy Market Share (%), By End-user, 2017-2031F
Figure 75 South America Gene Therapy Market Share (%), By Country, 2017-2031F
Figure 76 Brazil Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 77 Brazil Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 78 Middle East & Africa Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 79 Middle East & Africa Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 80 Middle East & Africa Gene Therapy Market Share (%), By Type, 2017-2031F
Figure 81 Middle East & Africa Gene Therapy Market Share (%), By Vector, 2017-2031F
Figure 82 Middle East & Africa Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
Figure 83 Middle East & Africa Gene Therapy Market Share (%), By Application, 2017-2031F
Figure 84 Middle East & Africa Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
Figure 85 Middle East & Africa Gene Therapy Market Share (%), By End-user, 2017-2031F
Figure 86 Middle East & Africa Gene Therapy Market Share (%), By Country, 2017-2031F
Figure 87 Saudi Arabia Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 88 Saudi Arabia Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 89 UAE Gene Therapy Market, By Value, In USD Million, 2017-2031F
Figure 90 UAE Gene Therapy Market, By Volume, In Thousand Therapies, 2017-2031F
Figure 91 By Type Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 92 By Vector Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 93 By Gene Delivery Method Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 94 By Application Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 95 By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 96 By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 97 By Region Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 98 Revenues of Top Five Players Operating in Gene Therapy Market, in USD Million, 2023
List of Table:
Table 1. Competition Matrix of Top Five Market Leaders
Table 2. About Us - Regions and Countries Where We Have Executed Client Projects
Global coffee market is expected to experience growth due to consumers’ increasing preference for organic and premium coffee that offers freshness, superior quality of beans and roasts, and unique flavor profile. Additionally, the product innovation,....Read More
Published on
July 2024
4,500
Global home theater system market is expected to experience growth due to technological advancements, increasing disposable incomes, rising demand for high-definition content, integration with smart home systems, and the surge in streaming services p....Read More
Published on
July 2024
4,500
Global baby food market is expected to experience growth due to factors such as consumers’ increasing awareness of the nutrients which are essential for babies development and introduction of wide variety of baby foods in the market from milk powders....Read More
Published on
July 2024
4,500
Global isoflavones market is expected to experience growth due to increasing consumer health awareness, rising demand for functional foods and nutraceuticals, advancements in extraction technologies, and expanding applications in cosmetics, pharmaceu....Read More
Published on
July 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US